LEXINGTON, Mass., June 20, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of PTx's Marketing Authorisation Application (MAA) for IMREPLYS®...
Hence then, the article about european medicines agency chmp recommends eu approval of partner therapeutics imreplys sargramostim rhu gm csf to treat exposure to myelosuppressive doses of radiation haematopoietic sub syndrome of acute radiation syndrome was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( European Medicines Agency CHMP Recommends EU Approval of Partner Therapeutics IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Haematopoietic Sub-syndrome of Acute Radiation Syndrome) )
Also on site :
- Stunning ISS Photo of Florida, Cuba Captures & 039;Moonglint& 039;
- Saudi-led coalition strikes Yemeni port over unauthorised weapons shipment
- Will Cristiano Ronaldo play tonight for Al-Nassr vs Al Ettifaq in SPL 2025-26?